Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its ...

Market Position and Competition Blueprint Medicines has established a strong position in the treatment of mast cell-driven diseases, with Ayvakit leading the market for systemic mastocytosis.

Sanofi has completed its acquisition of Blueprint Medicines, enhancing its portfolio with a commercialised therapy and the expertise of a company focused on systemic mastocytosis (SM) and other ...

In other recent news, Blueprint Medicines has announced its acquisition by Sanofi in a deal valued at approximately $9.5 billion.

An update from Blueprint Medicines ( (BPMC)) is now available. On July 17, 2025, Blueprint Medicines completed a merger that resulted in the full prepayment and termination of its existing ...

Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its portfolio a commercialized medicine, a promising ...

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its ...

Sanofi completes acquisition of Blueprint Medicines. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation, adding to its portfolio a commercialized medicine ...

In other recent news, Blueprint Medicines has announced its acquisition by Sanofi in a deal valued at approximately $9.5 billion. The acquisition includes a cash payment of $129 per share and ...

Sanofi, an R&D driven, AI-powered biopharma company, announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its portfolio a commercialized medicine, a ...